Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -13.27% | -14.04% | 2.00% | -0.38% | 1.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.27% | -14.04% | 2.00% | -0.38% | 1.84% |
| Cost of Revenue | 0.98% | 3.77% | 20.55% | 29.64% | 27.42% |
| Gross Profit | -19.67% | -21.37% | -5.24% | -10.35% | -6.57% |
| SG&A Expenses | 11.38% | 3.66% | -2.60% | -6.65% | -8.93% |
| Depreciation & Amortization | -32.34% | -27.99% | -23.68% | -12.88% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.20% | -1.25% | -0.94% | -0.22% | -1.20% |
| Operating Income | -427.75% | -549.09% | 81.55% | -8.32% | 349.03% |
| Income Before Tax | -3.54% | -1,165.17% | -900.17% | -843.71% | -32.44% |
| Income Tax Expenses | -95.19% | -46.85% | -78.77% | -98.74% | -79.60% |
| Earnings from Continuing Operations | -0.49% | -1,570.56% | -528.43% | -236.62% | -13.27% |
| Earnings from Discontinued Operations | -- | 109.10% | 108.70% | 110.41% | 118.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.09% | -2,177.79% | -366.29% | -109.14% | 14.40% |
| EBIT | -427.75% | -549.09% | 81.55% | -8.32% | 349.03% |
| EBITDA | -155.41% | -137.46% | 15.72% | -19.69% | 8.56% |
| EPS Basic | 27.10% | -2,239.87% | -220.34% | -69.28% | 33.83% |
| Normalized Basic EPS | -272.25% | -338.26% | -602.10% | -254.33% | 73.33% |
| EPS Diluted | 46.63% | -344.18% | -118.32% | -98.15% | -9.14% |
| Normalized Diluted EPS | -103.70% | -444.04% | -1,353.85% | -493.35% | 47.49% |
| Average Basic Shares Outstanding | 96.26% | 53.54% | 38.75% | 25.33% | 13.42% |
| Average Diluted Shares Outstanding | 82.16% | 49.05% | 54.88% | 66.69% | 47.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |